Please use this identifier to cite or link to this item:
Title: Update about Oralair® as a treatment for grass pollen allergic rhinitis
Author: Klimek, Ludger
Brehler, Randolf
Mösges, Ralph
Demoly, Pascal
Mullol i Miret, Joaquim
Wang, De Yun
O'Hehir, Robyn
Didier, Alain
Kopp, Matthias Volkmar
Bos, Catherine
Karagiannis, Efstratios
Keywords: Rinitis
Issue Date: 15-Jun-2022
Publisher: Taylor and Francis
Abstract: Sublingual immunotherapy (SLIT) is a well-tolerated, safe, and effective approach to treating allergic rhinitis (AR). Oralair (R) is a five-grass pollen SLIT tablet containing natural pollen allergens from five of the major grass species responsible for seasonal AR due to grass pollen allergy. Recommended use is in a pre-coseasonal regimen, starting daily treatment approximately 4 months before the start of the pollen season, with treatment then continued daily throughout the season; treatment should continue for 3-5 y. Clinical efficacy and safety of Oralair (R) in patients with grass pollen-induced AR has been demonstrated in a comprehensive clinical development program of randomized controlled trials. Effectiveness has been substantiated in subsequent observational studies with sustained efficacy following treatment cessation and a favorable level of adherence, quality of life, benefit, and satisfaction for the patients. Supportive evidence for a benefit in reducing the risk or delaying the development of allergic asthma is emerging.
Note: Reproducció del document publicat a:
It is part of: Human Vaccines & Immunotherapeutics, 2022, vol. 18, num. 5
Related resource:
ISSN: 2164-554X
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
Update_about_Oralair.pdf730.62 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons